Learn about cystic fibrosis, a genetic disorder that affects the lungs, pancreas, and other organs, and how to treat and live with this chronic disease.
CF is a rare genetic disease found in about 30,000 people in the U.S. If you have CF or are considering testing for it, knowing about the role of genetics in CF can help you make informed decisions about your health care.
If you or your child has just been diagnosed with cystic fibrosis, or your doctor has recommended testing for CF, you may have many questions.
Diagnosing CF is a multistep process. A complete diagnostic evaluation should include a newborn screening, a sweat chloride test, a genetic or carrier test, and a clinical evaluation at a CF Foundation-accredited care center.
Raising a child with cystic fibrosis can bring up many questions because CF affects many aspects of your child’s life. Here you’ll find resources to help you manage your child’s daily needs and find the best possible CF care.
Living with cystic fibrosis comes with many challenges, including medical, social, and financial. By learning more about how you can manage your disease every day, you can ultimately help find a balance between your busy lifestyle and your CF care.
People with CF are living longer, healthier lives than ever before. As an adult with CF, you may reach key milestones you might not have considered. Planning for these life events requires careful thought as you make decisions that may impact your life.
People with cystic fibrosis are living longer and more fulfilling lives, thanks in part to specialized CF care and a range of treatment options.
Cystic Fibrosis Foundation-accredited care centers provide expert care and specialized disease management to people living with cystic fibrosis.
We provide funding for and accredit more than 120 care centers and 53 affiliate programs nationwide. The high quality of specialized care available throughout the care center network has led to the improved length and quality of life for people with CF.
The Cystic Fibrosis Foundation provides standard care guidelines based on the latest research, medical evidence, and consultation with experts on best practices.
As a clinician, you’re critical in helping people with CF maintain their quality of life. We’re committed to helping you partner with patients and their families by providing resources you can use to improve and continue to provide high-quality care.
As part of the Cystic Fibrosis Foundation's mission to help improve the lives of people living with cystic fibrosis, the PSDC initiative taps the CF community to inform key efforts to support the management of daily care.
Your cystic fibrosis care team includes a group of CF health care professionals who partner with you to provide specialized, comprehensive CF care.
Many people living with cystic fibrosis and their families face complicated issues related to getting the care they need. Cystic Fibrosis Foundation Compass makes sure that no one has to do it alone.
CF Foundation Compass is a service that helps people with CF and their families with navigating insurance options, connecting to legal information and experts, finding available financial resources, and tackling other life issues.
CF care team members are paramount in providing highly specialized care to people living with CF. CF Foundation Compass can help by serving as a strategic ally for care teams, so team members can focus on their patients’ care.
CF Foundation Compass can help you navigate insurance, financial, legal, and other issues you are facing. Use this online form to start your conversation with a Compass case manager today.
The Cystic Fibrosis Foundation is the world’s leader in the search for a cure for CF and supports a broad range of research initiatives to tackle the disease from all angles.
The CF Foundation offers a number of resources for learning about clinical trials and treatments that are being developed to improve the treatment of cystic fibrosis.
Our understanding of CF continues to evolve as scientists study what causes the disease and how it affects the body. These insights drive the development of new and better treatments and bring us one step closer to a cure.
Researchers, supported by the CF Foundation, have made tremendous advances to improve the health and quality of life of people with CF. We are committed to providing the tools and resources you need to continuously build upon this work.
The Cystic Fibrosis Foundation supports two programs that provide funds to biotechnology and pharmaceutical companies for development of new pharmaceutical products to benefit individuals with cystic fibrosis: The Therapeutics Development Award (TDA) and the Path to a Cure (PTAC): Industry Award programs.
By supporting early to mid-phase drug development activities with both financial and technical support, the Cystic Fibrosis Foundation's Therapeutics Development Award (TDA) program is designed to stimulate and de-risk CF drug development of novel therapies for cystic fibrosis. The program provides companies with funding and other resources to support studies that may include drug discovery; pre-clinical safety; pharmacokinetics/pharmacodynamics (PK/PD); and clinical studies in people with CF through Phase 2 development.
Applications will be considered in any therapeutic area that could benefit people with CF but are particularly encouraged in areas related to treating CF infections, CFTR modulation, mucus clearance (mucolytics and airway surface hydration), inflammation, chronic lung allograft dysfunction, CF-related diabetes, CF liver disease, and nutrition.
To be funded through this mechanism, organizations are expected to provide internal funds that at least match the level of CF Foundation support. Generally, Foundation support may not be used for manufacturing and controls (CMC production), to conduct clinical trials in only healthy human subjects, or to support senior personnel engaged in administrative roles without specific approval by the Foundation.
The TDA program provides two mechanisms of support:
Award pay-out is typically milestone-based. If a TDA contributes to successful regulatory marketing approval, the CF Foundation will receive reimbursement plus a multiple and/or a percentage of net sales. Terms are negotiated prior to finalizing the award. If a program is unsuccessful, no payback is expected.
The Path to a Cure (PTAC) initiative is the Foundation's ambitious research program to support development of treatments for the underlying cause of the disease and, ultimately, a cure for every person with CF.
Although significant breakthroughs are helping people with CF live longer and healthier lives, there are still many individuals who will not benefit from CFTR modulators. Therefore, the Foundation is prioritizing efforts to identify innovative therapeutic approaches for these people with CF.
Industry programs supported through the PTAC initiative will focus on two core strategies to address the underlying cause of CF:
The Foundation intends to allocate $500 million through 2025 for these efforts and is challenging potential collaborators to submit proposals that will accelerate the pace of progress for CF drug discovery and development in areas that include, but are not necessarily limited to, the following priority areas:
Any commercial programs developing therapies or therapeutic platforms with the potential to advance these goals will be seriously considered. The amounts of awards given through the PTAC initiative are expected to be substantially higher than those through the TDA program -- up to tens of millions of dollars. Contract terms are negotiated prior to finalization of the agreement.
In addition to funding, the Foundation offers partners a range of resources to de-risk CF drug discovery and development. This includes access to a robust community of leading academic researchers, preclinical CF-related model systems, infrastructure for preclinical development, and access to the world's largest network of CF clinical trial sites. Additionally, consulting advice on trial design is supported through the Therapeutics Development Network Coordinating Center.
Learn more about the Path to a Cure.
Please review the appropriate Policies and Guidelines for complete submission information:
For those who seek support through the TDA or PTAC program and want to ensure the proposal is within the scope of research that supports the CF Foundation's mission, investigators should submit a letter of intent (LOI) for initial CF Foundation review in advance of a full proposal.
Both LOI and full submissions are accepted throughout the calendar year, although it is highly unlikely that submissions not received by October 31 will be funded in that calendar year.
Applicants are to submit LOIs and full applications online at proposalCENTRAL.
For further information or to discuss the potential relevance of studies for this program, please contact Lindsey Beaman, email@example.com, and/or Maria Wang, firstname.lastname@example.org.
Share this Page
Follow Us On
With more than 70 chapters and offices across the country, there are plenty of ways to get involved.
Cystic Fibrosis Foundation
4550 Montgomery Ave.
Suite 1100 N
Bethesda, MD 20814
800-344-4823 (toll free)
Sign up for our emails